P & G Health Ltd

Which are the latest news on P & G Health Ltd?

Why is Procter & Gamble Health Ltd falling/rising?

As of 05-Sep, Procter & Gamble Health Ltd's stock price is declining, currently at 5,657.90, due to underperformance against its sector, lower moving averages, decreased investor participation, poor long-term growth prospects, and reduced institutional investment. These factors collectively indicate negative sentiment surrounding the stock.

As of 05-Sep, Procter & Gamble Health Ltd's stock price is falling, currently at 5,657.90, reflecting a decrease of 104.3 points or 1.81%. This decline can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has underperformed its sector by 1.5% today, indicating a weaker performance relative to its peers. Additionally, the stock's moving averages show that it is lower than the 5-day, 20-day, 50-day, and 100-day moving averages, suggesting a downward trend in the short term. There has also been a notable decrease in investor participation, with delivery volume falling by 33.67% compared to the 5-day average, which may signal reduced interest from investors.<BR><BR>Furthermore, the company's long-term growth prospects appear poor, with net sales growing at an annual rate of only 7.27% and operating profit at 15.39% over the last five years. The stock has generated a return of -12.42% over the past year, despite a 10.9% increase in profits, which indicates a high PEG ratio of 2.6, suggesting that the stock may be overvalued relative to its earnings growth.<BR><BR>Institutional investors have also decreased their stake by 1.1% in the previous quarter, which could reflect a lack of confidence in the stock's future performance. This decline in institutional interest, combined with the company's flat results reported in June, contributes to the overall negative sentiment surrounding the stock.<BR><BR>In summary, the combination of underperformance against benchmarks, declining investor participation, poor long-term growth metrics, and reduced institutional investment are key factors contributing to the falling stock price of Procter & Gamble Health Ltd.

Should I buy, sell or hold Procter & Gamble Health Ltd?

Who are in the management team of P & G Health Ltd?

The management team of P & G Health Ltd includes S N Talwar (Chairman), Milind Thatte (Managing Director), Amit Gupta (CFO), and several directors, including independent and non-executive members, overseeing the company's operations and strategy.

The management team of P & G Health Ltd includes the following individuals:<BR><BR>1. **S N Talwar** - Chairman & Independent Director<BR>2. **Rani A Jadhav** - Independent Director<BR>3. **Milind Thatte** - Managing Director<BR>4. **Amit Gupta** - Director (Finance) & CFO<BR>5. **Aalok Agrawal** - Director<BR>6. **Zeal Shah** - Company Secretary & Compliance Officer<BR>7. **Elizabeth Desmond** - Director<BR>8. **S Madhavan** - Independent Director<BR>9. **Lokesh Chandak** - Executive Director<BR>10. **Seema Sambasivan** - Non-Executive Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does P & G Health Ltd do?

Procter & Gamble Health Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, specializing in health products. As of June 2026, it reported net sales of 364 Cr and a net profit of 96 Cr, with a market cap of INR 9,400 Cr.

Overview:<BR>Procter & Gamble Health Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>Procter & Gamble Health Ltd was incorporated in 1967 as E Merck (India) Limited. The company underwent several name changes, first to Merck Limited on March 27, 2002, and then to its current name on May 6, 2019. The latest quarterly results reported net sales and net profit for the period ending June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 364 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 96 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 9,400 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 29.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 3.62%<BR>- Debt Equity: -0.36<BR>- Return on Equity: 64.14%<BR>- Price to Book: 18.11<BR><BR>Contact Details:<BR>Address: Godrej One 8th Floor, Projshanagar Vikhroli (East) Mumbai Maharashtra : 400079<BR>Tel: 91-22-62109000<BR>Email: investorgrievance.im@pg.com<BR>Website: http://www.pghealthindia.com

Who are the peers of the P & G Health Ltd?

P & G Health Ltd's peers include Akums Drugs, Viyash Scientifi, Blue Jet Health, Sanofi Consumer, Strides Pharma, Aarti Pharma, Sanofi India, Senores Pharma, and SPARC. In terms of performance, Akums Drugs leads with a 1-year return of 70.88%, while P & G Health Ltd has a return of -9.48%.

Peers: The peers of P & G Health Ltd are Akums Drugs, Viyash Scientifi, Blue Jet Health, Sanofi Consumer, Strides Pharma, Aarti Pharma, Sanofi India, Senores Pharma, and SPARC.<BR><BR>Quality Snapshot: Excellent management risk is observed at P & G Health Ltd, Sanofi Consumer, and Sanofi India, while Average management risk is found at Akums Drugs, Strides Pharma, Aarti Pharma, Senores Pharma, and SPARC. Below Average management risk is noted for Viyash Scientifi. Growth is Good at Viyash Scientifi and Strides Pharma, while Average growth is seen at Akums Drugs, Aarti Pharma, and P & G Health Ltd. Below Average growth is reported for Blue Jet Health, Sanofi Consumer, Sanofi India, and the rest. Excellent capital structure is present at Akums Drugs, Blue Jet Health, Sanofi Consumer, P & G Health Ltd, Aarti Pharma, and the rest, while Below Average capital structure is noted for Viyash Scientifi, Strides Pharma, and SPARC.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Akums Drugs at 70.88%, while the lowest is Sanofi India at -39.16%. P & G Health Ltd has a 1-year return of -9.48%, which is higher than Sanofi India but lower than Akums Drugs. Additionally, Sanofi India and Sanofi Consumer have negative six-month returns.

How big is P & G Health Ltd?

As of 31st August, Procter & Gamble Health Ltd has a market capitalization of 9,400.00 Cr, with recent Net Sales of 1,432.94 Cr and a Net Profit of 356.88 Cr.

As of 31st August, Procter & Gamble Health Ltd has a market capitalization of 9,400.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,432.94 Cr and a Net Profit of 356.88 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with Shareholder's Funds amounting to 524.55 Cr and Total Assets of 810.65 Cr.

Are Procter & Gamble Health Ltd latest results good or bad?

Procter & Gamble Health Ltd's latest Q4 FY26 results are generally positive, with a net profit increase of 54.62% year-on-year, but a slight revenue decline of 0.91% quarter-on-quarter raises concerns about sustaining growth. Overall, strong profitability metrics contrast with challenges in revenue momentum.

Procter & Gamble Health Ltd's latest results for Q4 FY26 can be characterized as generally positive, particularly in terms of profitability metrics. The company reported a net profit of ₹94.60 crores, which is a substantial increase of 54.62% year-on-year and 22.07% quarter-on-quarter. This strong profit growth reflects effective cost management and operational efficiency.<BR><BR>However, there are some concerns regarding revenue growth. Net sales for the quarter were ₹370.45 crores, which represents a slight decline of 0.91% compared to the previous quarter, although it shows a healthy increase of 19.12% year-on-year. This sequential dip in sales may raise questions about the company's ability to sustain revenue momentum.<BR><BR>On the positive side, the operating margin reached a record high of 36.60%, which is a significant improvement from previous quarters. The return on equity (ROE) is also impressive at 47.36%, indicating strong capital efficiency.<BR><BR>In summary, while the profitability metrics are robust and show significant improvement, the slight decline in quarterly sales could be a concern for long-term growth prospects. Overall, the results reflect a mixed picture: strong profitability but challenges in sustaining revenue growth.

How has been the historical performance of P & G Health Ltd?

P & G Health Ltd experienced a decline in net sales and profitability in June 2024, with net sales at 1,151.26 Cr, down from 1,229.62 Cr in June 2023, and profit after tax decreasing to 200.98 Cr from 229.47 Cr. Overall, the company faced challenges with reduced sales, profits, and asset values.

Answer:<BR>The historical performance of P & G Health Ltd shows a fluctuating trend in net sales and profitability over the years. <BR><BR>Breakdown:<BR>In June 2024, P & G Health Ltd reported net sales of 1,151.26 Cr, a decrease from 1,229.62 Cr in June 2023, but an increase from 1,114.41 Cr in June 2022. The total operating income for June 2024 was 1,151.26 Cr, reflecting a similar trend. The company experienced a total expenditure of 845.26 Cr in June 2024, down from 904.94 Cr in June 2023, leading to an operating profit (PBDIT) of 321.63 Cr, which was lower than the 343.07 Cr reported in the previous year. Profit before tax also decreased to 273.32 Cr in June 2024 from 314.20 Cr in June 2023, resulting in a profit after tax of 200.98 Cr, down from 229.47 Cr. The earnings per share (EPS) for June 2024 was 121.07, a decline from 138.23 in June 2023. The company's total assets as of June 2024 were 760.67 Cr, down from 1,075.87 Cr in June 2023, while total liabilities decreased to 760.67 Cr from 1,075.87 Cr. Cash flow from operating activities was 228.00 Cr in June 2024, compared to 236.00 Cr in June 2023, indicating a slight decline in cash generation capabilities. Overall, the financial metrics indicate a challenging year for P & G Health Ltd, with declines in sales, profits, and asset values.

Is P & G Health Ltd technically bullish or bearish?

As of October 6, 2025, the trend is mildly bullish due to daily moving averages and Bollinger Bands, but tempered by mildly bearish weekly MACD and KST indicators, suggesting a cautious bullish outlook.

As of 6 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the Bollinger Bands showing a similar trend on both weekly and monthly time frames. However, the weekly MACD and KST are mildly bearish, which tempers the overall bullish sentiment. The Dow Theory also reflects a mildly bearish stance on the weekly chart, while remaining bullish on the monthly. Overall, the mixed signals suggest a cautious bullish outlook.

Who are the top shareholders of the P & G Health Ltd?

The top shareholders of P & G Health Ltd include Procter And Gamble Overseas India B.V. with 51.82%, mutual funds at 10.54%, foreign institutional investors at 6.87%, and Nippon Life India Trustee Ltd as the largest public shareholder at 4.1%. Individual investors collectively own 21.9% of the company.

The top shareholders of P & G Health Ltd include Procter And Gamble Overseas India B.V., which holds the largest stake at 51.82%. The company also has a diverse shareholder base, with mutual funds holding 10.54% across 11 schemes and foreign institutional investors (FIIs) holding 6.87% through 120 different entities. The highest public shareholder is Nippon Life India Trustee Ltd, which holds 4.1%. Additionally, individual investors collectively own 21.9% of the company.

When is the next results date for P & G Health Ltd?

No Upcoming Board Meetings

Has P & G Health Ltd declared dividend?

Procter & Gamble Health Ltd has declared an 800% dividend, amounting to 80 per share, with an ex-date of February 21, 2025. The company has demonstrated strong total returns, particularly over longer periods, with a 44.84% return over the last 5 years.

Procter & Gamble Health Ltd has declared an 800% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 800%<BR>- Amount per share: 80<BR>- Ex-date: 21 Feb 25<BR><BR>Dividend Yield: 2.51%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 0.61%, the dividend return was 1.43%, resulting in a total return of 2.04%.<BR><BR>Over the past year, the price return stood at 12.45%, with a dividend return of 2.79%, leading to a total return of 15.24%.<BR><BR>For the 2-year period, the price return was 5.24%, the dividend return was 6.69%, culminating in a total return of 11.93%.<BR><BR>In the 3-year span, the price return reached 27.68%, the dividend return was 9.96%, resulting in a total return of 37.64%.<BR><BR>Over the last 4 years, the price return was -4.36%, while the dividend return was 9.08%, leading to a total return of 4.72%.<BR><BR>Finally, in the 5-year period, the price return was 30.81%, the dividend return was 14.03%, resulting in a total return of 44.84%.<BR><BR>Overall, Procter & Gamble Health Ltd has shown a strong dividend declaration alongside positive total returns, particularly in the longer-term periods, indicating a solid performance for investors.